Phase 2, Phase 3 Recruiting Academic/Other
This Phase II/III trial will evaluate the what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor DNA (ctDNA) after surgery for colon cancer.
Sponsor: NRG Oncology
NCT ID: NCT05174169
Sites in Pennsylvania: - Lehigh Valley Hospital-Cedar Crest — Allentown, Pennsylvania
- UPMC Altoona — Altoona, Pennsylvania
- UPMC-Heritage Valley Health System Beaver — Beaver, Pennsylvania
- Lehigh Valley Hospital - Muhlenberg — Bethlehem, Pennsylvania
- UPMC Hillman Cancer Center at Butler Health System — Butler, Pennsylvania
Phase 3 Recruiting Network
This phase III trial evaluates whether a web-based intervention called Current Together after Cancer (CTAC) works to increase the number of patients with surgically removed (resected) colorectal cancer who receive surveillance care that al…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT07018869
Sites in Pennsylvania: - Lehigh Valley Hospital-Cedar Crest — Allentown, Pennsylvania
- Lehigh Valley Hospital - Muhlenberg — Bethlehem, Pennsylvania
- Christiana Care Health System-Concord Health Center — Chadds Ford, Pennsylvania
- Pocono Medical Center — East Stroudsburg, Pennsylvania
- Lehigh Valley Hospital-Hazleton — Hazleton, Pennsylvania
Phase 3 Recruiting Academic/Other
This phase III trial compares total ablative therapy and usual systemic therapy to usual systemic therapy alone in treating patients with colorectal cancer that has spread to up to 4 body sites (limited metastatic). The usual approach for …
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05673148
Sites in Pennsylvania: - Christiana Care Health System-Concord Health Center — Chadds Ford, Pennsylvania
- Geisinger Medical Center — Danville, Pennsylvania
- Penn State Milton S Hershey Medical Center — Hershey, Pennsylvania
- Lancaster General Ann B Barshinger Cancer Institute — Lancaster, Pennsylvania
- Geisinger Medical Oncology-Lewisburg — Lewisburg, Pennsylvania
Phase 3 Recruiting Industry
This study is being done to find out if tucatinib with other cancer drugs works better than standard of care to treat participants with HER2 positive colorectal cancer. This study will also determine what side effects happen when participa…
Sponsor: Seagen, a wholly owned subsidiary of Pfizer
NCT ID: NCT05253651
Sites in Pennsylvania: - UPMC Hillman Cancer Center - Beaver — Beaver, Pennsylvania
- UPMC Hillman Cancer Center at Butler Health System — Butler, Pennsylvania
- UPMC Hillman Cancer Center Erie — Erie, Pennsylvania
- UPMC Hillman Cancer Center at Arnold Palmer Pavilion, In Partnership with Excela Health — Greensburg, Pennsylvania
- UPMC Hillman Cancer Center - Pinnacle (Community Osteopathic / Medical Sciences Pavillion) — Harrisburg, Pennsylvania
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of standard-of-care chemotherapy and bevacizumab with or without INCA33890 in the first-line treatment of metastatic microsatellite stable colorectal cancer.
Sponsor: Incyte Corporation
NCT ID: NCT07284849
Sites in Pennsylvania: - St. Luke'S Health Network — Bethlehem, Pennsylvania
- Alliance Cancer Specialists — Doylestown, Pennsylvania
- Penn State Milton S. Hershey Medical Center — Hershey, Pennsylvania
- Hillman Cancer Center — Monroeville, Pennsylvania
- University of Pennsylvania — Philadelphia, Pennsylvania
Phase 3 Recruiting Network
This phase III trial compares hepatic arterial infusion (HAI) (pump chemotherapy) in addition to standard of care chemotherapy versus standard of care chemotherapy alone in treating patients with colorectal cancer that has spread to the li…
Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT05863195
Sites in Pennsylvania: - Lehigh Valley Hospital-Cedar Crest — Allentown, Pennsylvania
- Saint Vincent Hospital — Erie, Pennsylvania
- Jefferson Hospital — Jefferson Hills, Pennsylvania
- Forbes Hospital — Monroeville, Pennsylvania
- Fox Chase Cancer Center — Philadelphia, Pennsylvania
Phase 3 Recruiting Industry
The aim of this study is to compare progression free survival (PFS) in treatment-naïve participants with KRAS p.G12C mutated metastatic colorectal cancer (mCRC) receiving sotorasib, panitumumab and FOLFIRI vs FOLFIRI with or without bevaci…
Sponsor: Amgen
NCT ID: NCT06252649
Sites in Pennsylvania: - Thomas Jefferson University — Philadelphia, Pennsylvania
Phase 3 Recruiting Industry
The performance of SGM-101, an intraoperative imaging agent, will be compared to that of standard "white light" visualization during surgical resections of colorectal cancer.
Sponsor: Surgimab
NCT ID: NCT03659448
Sites in Pennsylvania: - Perelman Center for Advanced Medicine — Philadelphia, Pennsylvania
Phase 1, Phase 2 Recruiting Industry
This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: * Find the recommended dose of ART0380 that can be given safely to participants alone an…
Sponsor: Artios Pharma Ltd
NCT ID: NCT04657068
Sites in Pennsylvania: - University of Pennsylvania / Abramson Cancer Center — Philadelphia, Pennsylvania
- Thomas Jefferson University, Sidney Kimmel Cancer Center, Clinical Research Organization — Philadelphia, Pennsylvania
Phase 1, Phase 2 Recruiting Industry
The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors.
Sponsor: Parabilis Medicines, Inc.
NCT ID: NCT05919264
Sites in Pennsylvania: - University of Pennsylvania, Perelman School of Medicine — Philadelphia, Pennsylvania
- University of Pittsburgh Medical Center, Hillman Cancer Center — Pittsburgh, Pennsylvania
Phase 1, Phase 2 Recruiting Industry
This study is open to adults aged 18 years and older with different types of HER2+ cancer that has spread and cannot be removed by surgery. People can take part in this study if their tumours show HER2 aberrations and previous treatment wa…
Sponsor: Boehringer Ingelheim
NCT ID: NCT06324357
Sites in Pennsylvania: - Penn State Milton S. Hershey Medical Center — Hershey, Pennsylvania
Phase 2 Recruiting Industry
This is a Phase 2 study designed to determine the preliminary anti-tumor activity and confirm the safety of VV1 in combination with cemiplimab. The study will enroll patients with three distinct separate tumor cohorts. The cancers types ar…
Sponsor: Vyriad, Inc.
NCT ID: NCT04291105
Sites in Pennsylvania: - UPMC — Pittsburgh, Pennsylvania
Phase 2 Recruiting Industry
Colorectal cancer (CRC) is the third most common type of cancer diagnosed worldwide. The purpose of this study is to assess change in disease activity when telisotuzumab adizutecan is given alone compared to standard of care (SOC) given al…
Sponsor: AbbVie
NCT ID: NCT07023289
Sites in Pennsylvania: - Abramson Cancer Center at the University of Pennsylvania /ID# 275407 — Philadelphia, Pennsylvania
Phase 1, Phase 2 Recruiting Network
This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interf…
Sponsor: Children's Oncology Group
NCT ID: NCT04851119
Sites in Pennsylvania: - Children's Hospital of Philadelphia — Philadelphia, Pennsylvania
- Children's Hospital of Pittsburgh of UPMC — Pittsburgh, Pennsylvania
Phase 1, Phase 2 Recruiting Industry
This is a two-part, open-label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and anti- tumor activity of ETX-19477, a novel reversible s…
Sponsor: 858 Therapeutics, Inc.
NCT ID: NCT06395519
Sites in Pennsylvania: - Thomas Jefferson University, Sidney Kimmel Comprehensive Cancer Center — Philadelphia, Pennsylvania
Phase 1, Phase 2 Recruiting Industry
This study will assess the safety and efficacy of VS-7375 alone and in combination in patients with advanced solid tumors harboring a KRAS G12D-mutation.
Sponsor: Verastem, Inc.
NCT ID: NCT07020221
Sites in Pennsylvania: - Univ of Pennsylvania, Abramson Cancer Center — Philadelphia, Pennsylvania
Phase 1, Phase 2 Recruiting Industry
The goal of this clinical trial is to learn if an investigational drug CP-383 works to treat advanced cancer. It will also learn about the safety of CP-383. The main questions if aims to answer are: * Does CP-383 slow or stop the growth of…
Sponsor: Tasca Therapeutics
NCT ID: NCT07030257
Sites in Pennsylvania: - University of Pennsylvania — Philadelphia, Pennsylvania
Phase 1, Phase 2 Recruiting Industry
This is a Phase 1/2, multi-center, open-label basket study designed to evaluate the safety and anti-tumor activity of IDE196 in patients with solid tumors harboring GNAQ or GNA11 (GNAQ/11) mutations or PRKC fusions, including metastatic uv…
Sponsor: IDEAYA Biosciences
NCT ID: NCT03947385
Sites in Pennsylvania: - Sidney Kimmel Cancer Center at Thomas Jefferson University — Philadelphia, Pennsylvania
Phase 1, Phase 2 Recruiting Industry
Phase I/IIa image-guided, alpha-particle therapy study of \[203Pb\]Pb-PSV359 and \[212Pb\]Pb-PSV359 in patients with solid tumors that are known to be Fibroblast Activation Protein (FAP)-positive.
Sponsor: Perspective Therapeutics
NCT ID: NCT06710756
Sites in Pennsylvania: - University of Pittsburgh Medical Center — Pittsburgh, Pennsylvania
Phase 2 Recruiting Academic/Other
The purpose of this study is to find out whether the study drug, TSR-042, followed by standard chemoradiotherapy (the chemotherapy drug capecitabine + radiation therapy) and standard surgery is an effective treatment for advanced dMMR soli…
Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT04165772
Sites in Pennsylvania: - Lehigh Valley Health Network (Data Collection Only) — Allentown, Pennsylvania
Phase 2 Recruiting Industry
This clinical study is testing whether a new combination of medicines (DSP107 and atezolizumab) is more effective and safer than an existing treatment (fruquintinib) for people with advanced colorectal cancer that is microsatellite stable …
Sponsor: Kahr Bio Australia Pty Ltd
NCT ID: NCT07235293
Sites in Pennsylvania: - UPMC Hillman Cancer Center — Pittsburgh, Pennsylvania
Phase 2 Recruiting Industry
To assess: * efficacy of APL-101 as monotherapy for the treatment of NSCLC harboring MET Exon 14 skipping mutations, NSCLC harboring MET amplification, solid tumors harboring MET amplification, solid tumors harboring MET fusion, primary CN…
Sponsor: Apollomics Inc.
NCT ID: NCT03175224
Sites in Pennsylvania: - Penn State Milton S. Hershey Medical Center — Hershey, Pennsylvania
Phase 1, Phase 2 Recruiting Industry
The goal of this clinical trial is to evaluate CHM-2101, an autologous CDH17 CAR T-cell therapy for the treatment of advanced gastrointestinal (GI) cancers that are relapsed or refractory to at least 1 standard treatment regimen in the met…
Sponsor: Chimeric Therapeutics
NCT ID: NCT06055439
Sites in Pennsylvania: - University of Pennsylvania — Philadelphia, Pennsylvania
Phase 2 Recruiting Academic/Other
The study will evaluate patient and Health Care Professional- reported preference for Subcutaneous (SC) compared with IV nivolumab administration or similarly for SC compared with IV pembrolizumab.
Sponsor: Diwakar Davar
NCT ID: NCT07223424
Sites in Pennsylvania: - UPMC Hillman Cancer Center — Pittsburgh, Pennsylvania
Phase 1 Recruiting Industry
This first-in-human (FIH) dose-escalation and dose-validation/expansion study will assess KO-2806, a farnesyltransferase inhibitor (FTI), as a monotherapy and in combination, in adult patients with advanced solid tumors.
Sponsor: Kura Oncology, Inc.
NCT ID: NCT06026410
Sites in Pennsylvania: - UPMC Hillman Cancer Center — Pittsburgh, Pennsylvania